Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax (NASDAQ: NVAX ) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business. In its latest earnings report, Novavax included a few concerns that investors need to know about.

Why Is Novavax (NVAX) Stock Down 26% Today?

Reata Pharmaceuticals

Here are U.S. stocks in focus ahead of Wednesday's trading session:

Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts' over future operations

Novavax shares sank after the COVID-19 vaccine maker warned it has "substantial doubt" about its ability to stay in business through next year.

Novavax stock plunges 25% after the COVID-19 vaccine maker warns it could go out of business

Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates

Shares of the pharmaceutical company have slipped below $7 after trading well above $300 at points in 2021.

Novavax Stock Plunges 25% As Vaccine Maker Has ‘Substantial Doubt' About Staying In Business

Rivian Automotive

A couple of high-profile companies posted big declines in after-hours trading on Tuesday.

Rivian's Slamming on the Brakes, but This Vaccine Stock Is Falling Harder

Novavax Inc. NVAX shares shares sank in the extended session Tuesday after the biotech drug maker posted a wider-than-expected loss and reorganized with the appointment of a new chief executive. Novavax shares fell as much as 25% after hours, following a 6.8% rise in the regular session to close at $9.26.

Novavax stock sheds a quarter of its value after hours following revenue miss

COVID-19 vaccine maker Novavax Inc on Tuesday raised doubts about its ability to remain in business and announced plans to slash spending as it works to prepare for a fall vaccination campaign.

Novavax raises doubts about its ability to remain in business

Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive Officer Updated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023 Expanded Nuvaxovid™ label in adult booster and adolescent primary series Initiated Phase 2 trial of COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Company to host conference call today at 4:30 p.m.

Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Novavax is expected Tuesday to report narrowing losses and strong sales fourth-quarter sales growth. Ahead of the report, NVAX stock rose.

Here's The Good News For Novavax Ahead Of Its Fourth-Quarter Report

Inovio Pharmaceuticals

Both stocks soared during the coronavirus vaccine race, but their time has passed.

2 Stocks to Sell or Remove From Your Watchlist in 2023

Teladoc

Beaten-down growth stocks were popular buys during the fourth quarter for some of the brightest billionaire money managers.

3 Supercharged Growth Stocks Down 89% to 97% That Billionaires Can't Stop Buying

It doesn't seem like investors are looking forward to the company's fourth-quarter and full-year 2022 earnings release.

Why Novavax Stock Wilted on Wednesday

Provention Bio Inc

There is an argument for hitting the buy button, but it's important to consider the potential risks too.

2 Beaten-Down Stocks That Might Be too Cheap to Ignore

GAITHERSBURG, Md. , Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023

Is Novavax stock a buy as the company plans to update its Covid shot, in line with FDA experts' advice? Is NVAX stock a buy right now?

Novavax Plans To Update Its Covid Shot — But Is NVAX Stock A Buy Today?

Ocugen, Inc.

They skyrocketed before. It could happen again.

More Likely to 5x First: Novavax vs. Ocugen

You won't find Novavax's latest bad news trumpeted in a press release.

Is This the Telltale Sign to Sell Novavax Stock?

Novavax (NASDAQ: NVAX ) stock is on the move Monday after extending its Covid-19 vaccine agreement with the U.S. government. The U.S. Department of Health and Human Services ( HHS ) is working with the Department of Defense to order another 1.5 million doses of the Covid-19 vaccine made by Novavax.

NVAX Stock Alert: Novavax Will Provide 1.5 Million More Covid-19 Vaccine Doses to U.S.

Shares of Novavax Inc. NVAX, +1.02% gained 2.4% in premarket trading on Monday after the company said it will deliver additional doses of its updated COVID-19 booster to the U.S. government. Novavax said it will provide up to 1.5 million doses of the shot “for the upcoming 2023/2024 vaccination campaign.

Novavax to provide up to 1.5 million more doses of its COVID-19 vaccine to the U.S.

Modified agreement also includes the development of an updated vaccine in fall 2023 GAITHERSBURG, Md. , Feb. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

CRISPR Therapeutics

Etsy

All of these players are cheap today considering their growth potential.

These Cheap Growth Stocks Could Supercharge Your Portfolio

The landscape has shifted dramatically in the COVID-19 vaccine market.

Is Novavax Stock a Buy With the New Normal for COVID?

BioNTech SE

The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.

Better Buy: Novavax or BioNTech Stock?

At the start of 2023, vaccine developer Novavax, Inc. (NASDAQ: NVAX) saw a much-needed jump from near-historic lows. While they still have a long way to go before they can get back to the soaring levels of the Pandemic when they set a historical high of $320 in February of 2021, the jump is a welcomed change from their downward trend of the last year.

News for Novavax Stock (NVAX)